about
Prediction of high-grade vesicoureteral reflux after pediatric urinary tract infection: external validation study of procalcitonin-based decision rule[Childhood cerebral tumors: morbidity and follow-up into adulthood].Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours.Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: An innovative therapy for children with Cancer European Consortium Study.Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor studyPhase I study of non-pegylated liposomal doxorubicin in children with recurrent/refractory high-grade glioma.Procalcitonin is a predictor for high-grade vesicoureteral reflux in children: meta-analysis of individual patient data.[Tumors of the lateral ventricle in child: characteristics and specificities].Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumorsMortality in Children with Optic Pathway Glioma Treated with Up-Front BB-SFOP Chemotherapy.Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal diseaseMorbidity and tumor-related mortality among adult survivors of pediatric brain tumors: a review.Association of procalcitonin with acute pyelonephritis and renal scars in pediatric UTI.A French retrospective study on clinical outcome in 102 choroid plexus tumors in children.Influence of Nucleoshuttling of the ATM Protein in the Healthy Tissues Response to Radiation Therapy: Toward a Molecular Classification of Human Radiosensitivity.Parental smoking, maternal alcohol, coffee and tea consumption and the risk of childhood brain tumours: the ESTELLE and ESCALE studies (SFCE, France).Activity of the polyamine-vectorized anti-cancer drug F14512 against pediatric glioma and neuroblastoma cell lines.Rhabdoid component emerging as a subclonal evolution of paediatric glioneuronal tumours.Factors related to pregnancy and birth and the risk of childhood brain tumours: The ESTELLE and ESCALE studies (SFCE, France).Desmoid tumours of the head and neck in children: Review of management.Outcome and prognostic factors in high-risk childhood adrenocortical carcinomas: A report from the European Cooperative Study Group on Pediatric Rare Tumors (EXPeRT).Cilengitide targets pediatric glioma and neuroblastoma cells through cell detachment and anoikis induction.Which Variables Are Useful for Predicting Severe Infection in Children With Febrile Neutropenia?Predicting the risk of severe bacterial infection in children with chemotherapy-induced febrile neutropenia.Embryonal tumors with multilayered rosettes in children: the SFCE experience.[Usefulness of procalcitonin for the diagnosis of acute pyelonephritis in children][Diffuse intrinsic brain stem glioma in children: current treatment and future directions].Radiation-induced tumors in children irradiated for brain tumor: a longitudinal study."Classical 3 + 3 design" versus "accelerated titration designs": analysis of 270 phase 1 trials investigating anti-cancer agents.Efficacy of thalidomide in a child with histiocytic sarcoma following allogeneic bone marrow transplantation for T-ALL.EPT-13RAPIRI I – PHASE I STUDY OF DAILY ORAL RAPAMYCIN AND INTRAVENOUS IRINOTECAN IN CHILDREN WITH A RECURRENT/REFRACTORY MALIGNANT SOLID TUMOR: GOOD TOLERANCE AND PROMISING RESULTS IN BRAIN TUMORS - A REPORT FROM THE SOCIÉTÉ FRANÇAISE DES CANCERS EEPT-01DOSE-FINDING STUDY OF VINBLASTINE IN COMBINATION WITH NILOTINIB IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH REFRACTORY OR RECURRENT LOW-GRADE GLIOMA: RESULTS OF THE ITCC/SIOPE-BRAIN VINILO PHASE I TRIAL (NCT01887522).LG-32RHABDOID COMPONENT EMERGING AS A SUBCLONAL EVOLUTION OF PEDIATRIC GLIONEURONAL TUMORS.MB-106PROGNOSTIC RELEVANCE OF CLINICAL AND MOLECULAR RISK FACTORS IN CHILDREN WITH HIGH-RISK MEDULLOBLASTOMA TREATED IN THE FRENCH PROSPECTIVE TRIAL PNET HR + 5.PCM-13THE HYPOXIA-ACTIVATED PRODRUG EVOFOSFAMIDE (TH-302) IS EFFICACIOUS IN PEDIATRIC HIGH GRADE GLIOMA CELL LINES AS A MONOTHERAPY AND IN COMBINATION WITH CHEMOTHERAPIES.Correction: Prediction of High-Grade Vesicoureteral Reflux after Pediatric Urinary Tract Infection: External Validation Study of Procalcitonin-Based Decision Rule.Maternal residential pesticide use during pregnancy and risk of malignant childhood brain tumors: A pooled analysis of the ESCALE and ESTELLE studies (SFCE).Pediatric neurofibromatosis type 2: clinical and molecular presentation, management of vestibular schwannomas, and hearing rehabilitation.Cavernous malformations after cerebral irradiation during childhood: report of nine cases.Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2.
P50
Q28740746-D9F5586D-A8BA-4BAA-8593-D004B2625E22Q33370242-3D394D11-3DEC-4892-8D48-204E3B3C876EQ33390217-459968B2-01BA-4FFF-89BD-53D12F882B77Q33392287-439D9D34-B9CE-4B88-9E18-DB014F712D48Q33409117-1FEEA963-E125-44C5-9F03-A19C71F4312DQ33423926-A892E4B2-D680-40A5-B70D-86959267FCFBQ33879263-06279B29-BC58-47C4-9523-945FC1A575CCQ34056935-EF537EB2-DF56-42AC-9795-F39FB3522AADQ34480582-F8EBAB1C-4024-4248-86C2-A66819D67559Q35670831-4248A978-2CBE-40D5-A236-2BE21EBA706BQ37736041-95353DFD-6F80-4326-9E60-595679CD8D87Q37853458-D7F340BE-F210-4399-870C-F6CE87735AC9Q38102930-7A7749FA-27A6-499C-AD51-43264C5C265EQ38693611-59D74A17-6508-4F8F-B87B-9651E0323E9DQ38794946-9A2A4EED-96F9-435B-A35A-1AD08B81AAD6Q38801165-9B463F30-2F36-4870-9CDF-3715F39CA687Q38976825-76DD5347-3798-4F3A-9968-C1D8545FBC8BQ39039035-1B07F7B7-6550-469C-B20F-DCE321AAAA9CQ39039068-AD690EC0-7DDA-4F9E-847C-46914E7452E0Q39042173-0C803AF7-64EA-4E9B-87E0-4C020E1AAA05Q39106239-AB696763-C86E-4F75-84BA-C9FC5F41D399Q39144806-925CFB82-5EE6-49FC-A676-DCE6A5DE6828Q40134793-6D381283-CCEF-43F7-9538-B1FEEBF40FBAQ40349813-23043E46-193F-4494-8F67-EE6244A8E401Q40464649-1B038651-B443-400E-8848-73B553CDF867Q40508554-C21C2AF4-3CC1-4A28-9231-892BE21E20ADQ43216985-846B522F-3866-4D88-B3FF-7A3B374859DBQ43649551-48772CEB-EDAD-4AC9-92CC-34548016BE6AQ43684447-E3710F5B-0046-4E61-9770-641B7D1F1625Q44598673-A08A1079-4102-45F6-AED7-40964A9C6D31Q45787249-C4F6D13F-F6E5-4E6B-ADB1-EA14059A74C9Q46349129-E2041A68-F2B6-4CB1-9772-DBEDA597AC14Q46353166-34836888-A8AA-4084-AC89-1BA8B4269708Q46354134-D3CAC556-F4E9-46A9-A110-EFA9743C1EF8Q46357235-EEFB4378-6E89-4C0F-A3F3-162BDE736356Q46595953-C1BC1EC3-D2B1-4DA2-AE33-341203879F63Q47920966-03D67E4F-A84B-438E-BD58-B261C307FDE4Q48674799-7998CDC1-6568-476C-96BD-0AD476B75C86Q49128051-7FDE9B8D-B447-45BA-9C81-13C6389CB7E6Q50352494-F446C207-EFD1-4CF4-95D3-A7E4747205FD
P50
description
onderzoeker
@nl
researcher ORCID: 0000-0002-7088-2614
@en
name
Pierre Leblond
@ast
Pierre Leblond
@en
Pierre Leblond
@es
Pierre Leblond
@nl
type
label
Pierre Leblond
@ast
Pierre Leblond
@en
Pierre Leblond
@es
Pierre Leblond
@nl
prefLabel
Pierre Leblond
@ast
Pierre Leblond
@en
Pierre Leblond
@es
Pierre Leblond
@nl
P106
P31
P496
0000-0002-7088-2614